Rethinking multiple sclerosis therapy beyond clinical phenotypes
Clicks: 4
ID: 325277
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
4 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #106 of 373 articles by views in Brain research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 373 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Sormani et al. argue that multiple sclerosis should be viewed as a biological continuum rather than distinct clinical forms. Evidence from recent trials suggests that therapies targeting shared biological mechanisms can slow disability progression across the disease spectrum, supporting a shift away from traditional classifications.
| Reference Key |
openalex_W7203709716
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Maria Pia Sormani, Heinz Wiendl, Xavier Montalban, Jiwon Oh |
| Journal | Brain research |
| Year | 2026 |
| DOI |
10.1093/brain/awag273
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.